BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint

  • Srividya Swaminathan
  • Chuanxin Huang
  • Huimin Geng
  • Zhengshan Chen
  • Richard Harvey
  • Huining Kang
  • Carina Ng
  • Björn Titz
  • Christian Hurtz
  • Mohammed Firas Sadiyah
  • Daniel Nowak
  • Gabriela B Thoennissen
  • Vikki Rand
  • Thomas G Graeber
  • H Phillip Koeffler
  • William L Carroll
  • Cheryl L Willman
  • Andrew G Hall
  • Kazuhiko Igarashi
  • Ari Melnick
  • Markus Müschen

Abstract

The B cell-specific transcription factor BACH2 is required for affinity maturation of B cells. Here we show that Bach2-mediated activation of p53 is required for stringent elimination of pre-B cells that failed to productively rearrange immunoglobulin VH-DJH gene segments. After productive VH-DJH gene rearrangement, pre-B cell receptor signaling ends BACH2-mediated negative selection through B cell lymphoma 6 (BCL6)-mediated repression of p53. In patients with pre-B acute lymphoblastic leukemia, the BACH2-mediated checkpoint control is compromised by deletions, rare somatic mutations and loss of its upstream activator, PAX5. Low levels of BACH2 expression in these patients represent a strong independent predictor of poor clinical outcome. In this study, we demonstrate that Bach2(+/+) pre-B cells resist leukemic transformation by Myc through Bach2-dependent upregulation of p53 and do not initiate fatal leukemia in transplant-recipient mice. Chromatin immunoprecipitation sequencing and gene expression analyses carried out by us revealed that BACH2 competes with BCL6 for promoter binding and reverses BCL6-mediated repression of p53 and other cell cycle checkpoint-control genes. These findings identify BACH2 as a crucial mediator of negative selection at the pre-B cell receptor checkpoint and a safeguard against leukemogenesis.

Bibliographical data

Original languageEnglish
ISSN1078-8956
DOIs
Publication statusPublished - 08.2013
Externally publishedYes
PubMed 23852341